Inovio Pharmaceuticals (INO) Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
INO Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Inovio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$2.98 |
| 52 Week Low | US$0.56 |
| Beta | 1.51 |
| 1 Month Change | 11.32% |
| 3 Month Change | -12.59% |
| 1 Year Change | -39.80% |
| 3 Year Change | -76.74% |
| 5 Year Change | -98.88% |
| Change since IPO | -99.83% |
Recent News & Updates
INO: October FDA Decision And Cash Runway Will Shape Upside Potential
Inovio Pharmaceuticals' analyst price target has moved from $6 to $4 as analysts factor in recent financing dilution, updated fair value assumptions, and ongoing FDA review progress for the recurrent respiratory papillomatosis program. Analyst Commentary Recent Street research on Inovio Pharmaceuticals shows a mix of caution and optimism, with several bullish analysts highlighting specific company milestones and balance sheet factors that they see as supportive for the stock's current valuation and potential execution on its pipeline.
INO: Higher Share Count Will Set Stage For Future Upside Repricing
Analysts have reduced their price target for Inovio Pharmaceuticals by $0.50 to $2.50, citing the effect of a higher share count on their updated valuation work. What’s in the News for Inovio Pharmaceuticals Inovio Pharmaceuticals filed a follow-on equity offering that includes common stock and equity warrants, according to company event filings.INO: Rising Share Count Will Shape Future Upside Potential
Inovio Pharmaceuticals' updated fair value estimate has been revised from $13.00 to $6.00, reflecting analysts' lower price targets following recent research that cites a rising share count as a key factor in trimming expectations to $2.50. What's in the News Inovio Pharmaceuticals was added to the Russell 3000E Growth Benchmark, according to index constituent changes.Recent updates
INO: October FDA Decision And Cash Runway Will Shape Upside Potential
Inovio Pharmaceuticals' analyst price target has moved from $6 to $4 as analysts factor in recent financing dilution, updated fair value assumptions, and ongoing FDA review progress for the recurrent respiratory papillomatosis program. Analyst Commentary Recent Street research on Inovio Pharmaceuticals shows a mix of caution and optimism, with several bullish analysts highlighting specific company milestones and balance sheet factors that they see as supportive for the stock's current valuation and potential execution on its pipeline.INO: Higher Share Count Will Set Stage For Future Upside Repricing
Analysts have reduced their price target for Inovio Pharmaceuticals by $0.50 to $2.50, citing the effect of a higher share count on their updated valuation work. What’s in the News for Inovio Pharmaceuticals Inovio Pharmaceuticals filed a follow-on equity offering that includes common stock and equity warrants, according to company event filings.INO: Rising Share Count Will Shape Future Upside Potential
Inovio Pharmaceuticals' updated fair value estimate has been revised from $13.00 to $6.00, reflecting analysts' lower price targets following recent research that cites a rising share count as a key factor in trimming expectations to $2.50. What's in the News Inovio Pharmaceuticals was added to the Russell 3000E Growth Benchmark, according to index constituent changes.INO: Recent Equity Raises Will Set Up Future Repricing Potential
Analysts have reduced their price target on Inovio Pharmaceuticals stock from $3.00 to $2.50, citing the impact of a higher share count on projected fair value and valuation metrics. What’s in the News for Inovio Pharmaceuticals Inovio Pharmaceuticals completed a follow on equity offering of common stock and Series A and Series B warrants totaling US$17.5 million.Here's Why We're A Bit Worried About Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Shareholder Returns
| INO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.3% | 6.9% | -1.5% |
| 1Y | -39.8% | 45.3% | 17.9% |
Return vs Industry: INO underperformed the US Biotechs industry which returned 43.5% over the past year.
Return vs Market: INO underperformed the US Market which returned 18.8% over the past year.
Price Volatility
| INO volatility | |
|---|---|
| INO Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 112 | Jacqueline Shea | www.inovio.com |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.
Inovio Pharmaceuticals, Inc. Fundamentals Summary
| INO fundamental statistics | |
|---|---|
| Market cap | US$125.11m |
| Earnings (TTM) | -US$67.43m |
| Revenue (TTM) | n/a |
Is INO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$48.49m |
| Gross Profit | -US$48.49m |
| Other Expenses | US$18.94m |
| Earnings | -US$67.43m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 05:44 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inovio Pharmaceuticals, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Geoffrey Meacham | BofA Global Research |
| Raghuram Selvaraju | H.C. Wainwright & Co. |